GlassScriptPhysician profile
Laura M Moore
NPI 1710977822
$7,914.10
in general payments reported to CMS, 2019-2025
37 companies · $1,953 in 2025
The $1,953 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $124 · 2021: $510 · 2022: $902 · 2023: $1,952 · 2024: $2,159 · 2025: $1,953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,742 · Consulting Fee: $288 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,742.14 |
| Consulting Fee | $287.67 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,458.80 | 2020-2025 | Tezspire, Breztri, Airsupra |
| Amgen INC. | $1,129.54 | 2022-2025 | Tezspire |
| Genentech USA, INC. | $630.02 | 2021-2025 | Xolair, Polivy |
| Adma Biomanufacturing LLC | $531.63 | 2021-2025 | |
| Biocryst US Sales Co., LLC | $504.09 | 2022-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $478.03 | 2021-2025 | Takhzyro, Cuvitru, Glassia |
| Genzyme Corporation | $435.57 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $303.58 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $301.53 | 2020-2025 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Glaxosmithkline, LLC. | $239.16 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Teva Pharmaceuticals USA, INC. | $208.87 | 2019-2023 | Airduo Digihaler |
| Csl Behring | $204.40 | 2020-2025 | Hizentra, Andembry, Haegarda |
| Horizon Therapeutics Plc | $174.85 | 2020-2023 | Actimmune |
| Abbvie INC. | $150.91 | 2022-2023 | |
| Pharming Healthcare, INC. | $123.72 | 2021-2025 | Ruconest |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.